Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 2/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951710 | 1.00 | GAA (0.50) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL28246288 | 1.00 | GAA (0.50) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| Bicarbonate SCHEMBL9827045 | 0.97 | GAA (0.48) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL29842368 | 0.91 | MAPK1 (0.48) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL791466 | 0.91 | MAPK1 (0.48) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL31580592 | 0.91 | MAPK1 (0.48) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL953293 | 0.91 | GNAI3 (0.55) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL10442815 | 0.91 | KCNH2 (0.44) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL7365544 | 0.90 | EPHX1 (0.49) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL3332407 | 0.87 | NAAA (0.52) | GAAMAPK1HTTSMN1; SMN2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| CN-108349967-A | 1,3,4- thiadiazole compounds and its purposes in treating cancer | 阿斯利康(瑞典)有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-108349966-A | 1,3,4- thiadiazole compounds and its purposes in treating cancer | 阿斯利康(瑞典)有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-108349965-A | 1,3,4- thiadiazole compounds and its purposes in treating cancer | 阿斯利康(瑞典)有限公司 | 2018-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | GAA 192/4885MAPK1 2342/4885HTT 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.